Monday, June 15, 2026

March 8 in North Korea: Kim Jong Un Praises Women’s Contributions to Society

North Korea celebrated International Women's Day with a performance attended by Kim Jong Un, highlighting women's roles in society.

Powell Under Pressure—Can the President Fire the Fed Chair?

Trump threatens to dismiss Fed Chair Powell, but legal complexities may hinder his ability to do so, requiring Supreme Court approval.

The Bay of Pigs Invasion: How CIA’s 1961 Blunder Shaped U.S.-Cuba Relations

The Bay of Pigs invasion in 1961 highlights U.S. foreign policy failures, leading to Castro's power consolidation and Cold War tensions.

Tag: Celltrion

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Celltrion’s Groundbreaking Achievement: First Asian Bio Company to Secure APEC CBPR and Global CBPR Certifications

Celltrion becomes the first South Korean biotech firm to earn APEC CBPR and Global CBPR certifications, enhancing global data protection.

Celltrion’s 1 Trillion KRW Investment: A Game Changer for Biopharmaceutical Production by 2030

Celltrion plans a major expansion with over 1 trillion KRW investment, boosting production capacity for biosimilars and new drugs by 2030.

Why Celltrion’s STEQEYMA Auto-Injector is a Game Changer for Autoimmune Patients in North America

Celltrion expands its Steqeyma auto-injector lineup in Canada, enhancing market competitiveness and patient accessibility in North America.

How Zymfentra’s Prescription Rates Tripled in January: A Game-Changer for Celltrion

Celltrion's Zymfentra sees a 213% rise in U.S. prescriptions, marking significant growth since its launch, driven by market demand.

Celltrion’s Breakthrough: Why Vegzelma and Herzuma Lead in Japan’s Oncology Market

Celltrion's cancer treatments dominate the Japanese market, with Vegzelma and Herzuma capturing significant shares, showcasing strong growth.

How Celltrion Plans to Cut Biologics Development Costs by 25% Amid FDA Regulation Changes

Celltrion is optimistic about enhanced competitiveness due to eased biosimilar regulations by the FDA, expecting significant cost reductions.

Celltrion’s CT-P55: What Changes to FDA Clinical Trials Mean for Biosimilarity with Cosentyx?

Celltrion has applied to the FDA for changes to its Phase 3 trial of CT-P55, reducing participants to 153 to assess biosimilarity to Cosentyx.

Celltrion’s Ramucirumab and Infliximab: The Secrets Behind Their Dominance in Oceania’s Biopharmaceutical Market

Celltrion's cancer and autoimmune products are expanding market share in Australia and New Zealand, enhancing influence in Oceania.

How Celltrion’s Herceptin Biosimilar Herzuma Achieved 74% Market Share in Japan: A Game Changer for Cancer Treatment

Celltrion's Herzuma biosimilar captures 74% of Japan's trastuzumab market, enhancing patient access and leveraging favorable policies.

Celltrion’s Strategic Move: How Local Production in the U.S. Can Mitigate Tariff Risks

Celltrion outlines its Branchburg facility's operations and plans to mitigate tariff risks by establishing local production and a supply system.

CT-P55: How Celltrion’s New Biosimilar Approval Will Transform Clinical Trials in Europe

Celltrion receives EMA approval to reduce patient enrollment for CT-P55 trial, aiming to cut costs and duration of clinical development.

Celltrion’s Remsima Surpasses 1 Trillion KRW in Sales for 2nd Consecutive Year: What’s Driving Its Success?

Celltrion's Remsima treatment surpasses 1 trillion KRW in sales, driven by European market growth and new liquid formulation.

Celltrion Gets Global IB Upgrades: Morgan Stanley Raises Target to $206.25 as New Biosimilars Lift Margins

Celltrion is expanding through biosimilars and new drug development, attracting global investor interest and raising target stock prices.

How Celltrion’s Omlyclo is Dominating Spain’s Omalizumab Market: A First-Mover Success Story

Celltrion's Omlyclo treatment is thriving in Spain, capturing over 60% of the omalizumab market with innovative strategies and strong demand.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.